Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
* Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability.
* **Maintenance:** Usual maintenance dose is 10 mg to 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg daily). Some sources may suggest higher maximums based on specific protocols, but 40 mg daily is a common guideline.
## Pediatric Dosing
* **Ages 2 to less than 10 years OR weighing less than 30 kg:**
* **Initiation:** 5 mg once daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week.
* **Maintenance:** Usual maintenance dose is 5 mg to 10 mg twice daily.
* **Maximum Dose:** 10 mg twice daily (20 mg daily).
* **Ages 10 years or older OR weighing 30 kg or more:**
* Dosing is the same as for adults.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment is recommended, but lower doses may be appropriate.
* **Renal Impairment:** Use with caution. No specific dose adjustment is recommended, but lower doses may be appropriate.
## Contraindications
* Hypersensitivity to clobazam, other benzodiazepines, or any component of the formulation.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Sleep apnea syndrome.
## Adverse Effects
* **Common:** Somnolence, sedation, gait disturbance, fatigue, aggression, irritability, upper respiratory tract infection, constipation, anorexia, vomiting, insomnia, abnormal behavior, rash.
* **Serious:** Suicidal ideation and behavior, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms, respiratory depression, cognitive impairment, dependence.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depression. Coadministration should be approached with extreme caution, potentially requiring dose reduction of one or both agents.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam concentrations.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir):** May increase clobazam concentrations.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam concentrations.
* **Strong CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations.
* **Antiepileptic Drugs (AEDs):** Monitor for potential changes in efficacy or toxicity of concomitant AEDs.
## Monitoring
* Monitor for efficacy (reduction in seizure frequency).
* Monitor for adverse effects, particularly somnolence, sedation, and behavioral changes.
* Monitor for signs and symptoms of withdrawal upon discontinuation.
* Monitor for suicidal ideation and behavior.
* Monitor for skin reactions.
## Clinical Pearls
* Clobazam has a longer half-life compared to many other benzodiazepines, which may allow for less frequent dosing.
* Withdrawal symptoms can occur upon abrupt discontinuation, especially after prolonged use. Tapering the dose gradually is recommended.
* Clobazam can cause dose-dependent sedation. Titrate slowly to minimize this side effect.
* Due to the risk of serious skin reactions, patients should be advised to seek immediate medical attention if a rash develops.
* Use in combination with opioids may lead to profound sedation, respiratory depression, coma, and death.
***
**Disclaimer:** This information is intended for clinical use and does not replace current prescribing information. Always verify the most up-to-date drug information with official product labeling and relevant guidelines before patient care.
